NR in chronic kidney disease: metabolic changes, not kidney recovery

The main outcomes remained negative

NR research in chronic kidney disease has produced interesting biochemical findings without demonstrating kidney recovery or a general improvement in exercise capacity. A small crossover trial found no improvement in its primary exercise outcomes and no significant eGFR change. ^[1] A later paper examined inflammatory and cellular measures from the same trial. ^[2] That distinction matters because two publications can look like two confirmations when they are different analyses of the same participants. The evidence is useful for research planning, but it should not become a claim that a retail NAD precursor treats chronic kidney disease.

Twenty-five participants tried three conditions

The trial enrolled twenty-five adults with eGFR below 60 mL/min/1.73 m². Mean age was about sixty-one and mean eGFR about thirty-seven. Participants received oral NR at 1,000 mg daily, coenzyme Q10 at 1,200 mg daily and placebo in separate six-week periods, with washouts between them. ^[1] This was a randomized, blinded crossover design. NR and CoQ10 were alternative conditions, not a combination treatment. That detail should remain explicit when reading a product page that sells both together. The experiment cannot establish the effect of a blend it did not test.

Exercise and kidney measures need separate reading

Peak oxygen consumption, total work and total work efficiency did not improve significantly with NR or CoQ10. The report also found no significant change in eGFR. ^[1] Exploratory metabolic findings do not erase those results. A lower oxygen requirement at a particular submaximal workload is a different observation from improved maximal endurance or protection against progressive kidney disease. The reader should ask which result is being quoted before accepting a claim of better energy or kidney health. A positive secondary measurement and a negative primary outcome can coexist without either being misreported.

For the broader context, read NAD-related research in acute kidney injury.

The later paper is the same experiment

The 2025 companion report again describes twenty-five participants, the same amounts and six-week crossover conditions; its analyses included blood transcriptomics and a smaller cellular-bioenergetics subset. ^[2] It should be treated as additional information from the same research program, not an independent replication of clinical benefit. This is a common problem when counting studies by publication title. The number of papers is not the number of independent experiments. The useful question is whether a new group of participants reproduced a result, or whether investigators examined another set of outcomes in the original cohort.

Inflammation did not move in one direction

The companion analysis found an increase in IL-2 with NR, reductions in a measured oxidative-stress marker with both interventions and improved monocyte bioenergetic measures with NR in the assessed subset. ^[2] That is not a simple pattern in which every inflammatory signal fell. A broad anti-inflammatory claim would lose the actual direction of the results. These are specialized biological readouts, not a direct measure of how a patient feels or whether kidney disease is progressing. They can motivate further work without proving that the intervention is useful for every clinical purpose associated with inflammation.

Short-term tolerability has a limited scope

The original trial reported no serious adverse effects and no difference in treatment-associated adverse events compared with placebo over its short periods. ^[1] That is useful safety information for the tested regimen, not a guarantee for years of use or a person with a different clinical history. Kidney disease also changes the importance of coordination with the treating team. A patient should not add a precursor, change prescribed care or substitute an infusion on the basis of these findings. The preparation, medicines and clinical circumstances need review together, especially when a retail blend includes additional active ingredients.

Adjacent NR research cannot fill the clinical gap

A separate randomized trial in forty men with obesity used 2,000 mg oral NR daily for twelve weeks and did not improve insulin sensitivity or its major metabolic outcomes. ^[3] That population differs from CKD, but the result is a useful reminder that raising a pathway’s activity does not guarantee a general metabolic benefit. It cannot decide the kidney-disease question in either direction. Studies should contribute only what they measured. Combining their positive biochemical observations while ignoring their null clinical measures would create a more convincing commercial story than the actual evidence supports.

Why biomarker panels can sound more decisive than they are

Large molecular panels can generate detailed and visually impressive findings. They still need to be connected to a clinical question. If a source reports changes in gene-expression categories or lipid species, ask whether the study also demonstrated better function, fewer complications or a sustained disease benefit. The CKD trial illustrates the distinction: exploratory biology changed while the main exercise outcomes remained negative. ^{[1] [2]} The appropriate conclusion is not that every molecular result is meaningless. It is that the finding’s role is exploratory until an appropriately designed study demonstrates the outcome being claimed for the person considering treatment.

Keep the distinction clear with NAD+ biomarkers versus meaningful benefit.

What a patient or shopper should take away

For someone with CKD, these papers are material for a conversation with the nephrology team, not a self-treatment plan. For a general shopper, they show why the words NAD support cannot substitute for the actual population, preparation and endpoint. A clinically supervised trial of oral NR does not validate a home NAD injection or a combination supplement sold for kidney health. Compare products on clear formulation and practical terms, but keep the disease claim separate. The current narrow conclusion from this experiment is biological activity without demonstrated improvement in the principal functional or kidney measures.

For a separate practical comparison, see Pure Encapsulations NR Longevity review; a product review does not turn this study into a treatment recommendation.